Literature DB >> 30302023

The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.

My-Lan Kha1, Lisa Hesse1, Florian Deisinger1, Bence Sipos2, Christoph Röcken3,4, Alexander Arlt5, Susanne Sebens4,6, Ole Helm6, Heiner Schäfer7.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) exhibits one of the worst survival rates of all cancers. While death rates show declining trends in the majority of cancers, PDAC registers rising rates. Based on the recently described crosstalk between TGF-β1 and Nrf2 in the PDAC development, the involvement of ATF3 and its splice variant ΔZip2 in TGF-β1- and Nrf2-driven pancreatic tumorigenesis was investigated. As demonstrated here, PDAC (Panc1, T3M4) cells or premalignant H6c7 pancreatic ductal epithelial cells differentially express ΔZip2- and ATF3, relating to stronger Nrf2 activity seen in Panc1 cells and TGF-ß1 activity in T3M4 or H6c7 cells, respectively. Treatment with the electrophile/oxidative stress inducer tBHQ or the cytostatic drug gemcitabine strongly elevated ΔZip2 expression in a Nrf2-dependent fashion. The differential expression of ATF3 and ΔZip2 in response to Nrf2 and TGF-ß1 relates to differential ATF3-gene promoter usage, giving rise of distinct splice variants. Nrf2-dependent ΔZip2 expression confers resistance against gemcitabine-induced apoptosis, only partially relating to interference with ATF3 and its proapoptotic activity, e.g., through CHOP-expression. In fact, ΔZip2 autonomously activates expression of cIAP anti-apoptotic proteins. Moreover, ΔZip2 favors and ATF3 suppresses growth and clonal expansion of PDAC cells, again partially independent of each other. Using a Panc1 tumor xenograft model in SCID-beige mice, the opposite activities of ATF3 and ΔZip2 on tumor-growth and chemoresistance were verified in vivo. Immunohistochemical analyses confirmed ΔZip2 and Nrf2 coexpression in cancerous and PanIN structures of human PDAC and chronic pancreatitis tissues, respectively, which to some extent was reciprocal to ATF3 expression. It is concluded that depending on selective ATF3-gene promoter usage by Nrf2, the ΔZip2 expression is induced in response to electrophile/oxidative (here through tBHQ) and xenobiotic (here through gemcitabine) stress, providing apoptosis protection and growth advantages to pancreatic ductal epithelial cells. This condition may substantially add to pancreatic carcinogenesis driven by chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30302023     DOI: 10.1038/s41388-018-0518-3

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

1.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.

Authors:  Mitsuro Kanda; Hanno Matthaei; Jian Wu; Seung-Mo Hong; Jun Yu; Michael Borges; Ralph H Hruban; Anirban Maitra; Kenneth Kinzler; Bert Vogelstein; Michael Goggins
Journal:  Gastroenterology       Date:  2012-01-05       Impact factor: 22.682

2.  Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype.

Authors:  H Ouyang; Lj Mou; C Luk; N Liu; J Karaskova; J Squire; M S Tsao
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

3.  A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.

Authors:  X Yin; J W Dewille; T Hai
Journal:  Oncogene       Date:  2007-10-22       Impact factor: 9.867

4.  Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response.

Authors:  Hao-Yuan Jiang; Sheree A Wek; Barbara C McGrath; Dan Lu; Tsonwin Hai; Heather P Harding; Xiaozhong Wang; David Ron; Douglas R Cavener; Ronald C Wek
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

5.  ATF3 gene. Genomic organization, promoter, and regulation.

Authors:  G Liang; C D Wolfgang; B P Chen; T H Chen; T Hai
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

6.  The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis.

Authors:  Aijin Wang; Stacey Arantes; Leqin Yan; Kaoru Kiguchi; Mark J McArthur; Aysegul Sahin; Howard D Thames; C Marcelo Aldaz; Michael C Macleod
Journal:  BMC Cancer       Date:  2008-09-22       Impact factor: 4.430

Review 7.  The emerging role of the Nrf2-Keap1 signaling pathway in cancer.

Authors:  Melba C Jaramillo; Donna D Zhang
Journal:  Genes Dev       Date:  2013-10-15       Impact factor: 11.361

8.  The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1.

Authors:  Geeske Genrich; Marcus Kruppa; Lennart Lenk; Ole Helm; Anna Broich; Sandra Freitag-Wolf; Christoph Röcken; Bence Sipos; Heiner Schäfer; Susanne Sebens
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

9.  The Crosstalk between Nrf2 and TGF-β1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells.

Authors:  Sarah Arfmann-Knübel; Birte Struck; Geeske Genrich; Ole Helm; Bence Sipos; Susanne Sebens; Heiner Schäfer
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

10.  NRF2 Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell Reprogramming.

Authors:  Kate E Hawkins; Shona Joy; Juliette M K M Delhove; Vassilios N Kotiadis; Emilio Fernandez; Lorna M Fitzpatrick; James R Whiteford; Peter J King; Juan P Bolanos; Michael R Duchen; Simon N Waddington; Tristan R McKay
Journal:  Cell Rep       Date:  2016-02-18       Impact factor: 9.423

View more
  5 in total

1.  Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma.

Authors:  Ningna Weng; Siyuan Qin; Jiayang Liu; Xing Huang; Jingwen Jiang; Li Zhou; Zhe Zhang; Na Xie; Kui Wang; Ping Jin; Maochao Luo; Liyuan Peng; Edouard C Nice; Ajay Goel; Suxia Han; Canhua Huang; Qing Zhu
Journal:  Acta Pharm Sin B       Date:  2022-02-04       Impact factor: 14.903

2.  The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment.

Authors:  Thierry Voisin; Pascal Nicole; Valérie Gratio; Anaïs Chassac; Dounia Mansour; Vinciane Rebours; Anne Couvelard; Alain Couvineau
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine.

Authors:  Ryan N Fuller; Janviere Kabagwira; Paul A Vallejos; Andrew D Folkerts; Nathan R Wall
Journal:  Onco Targets Ther       Date:  2022-10-10       Impact factor: 4.345

Review 4.  New Discoveries and Ambiguities of Nrf2 and ATF3 Signaling in Environmental Arsenic-Induced Carcinogenesis.

Authors:  Zhuoyue Bi; Yao Fu; Priya Wadgaonkar; Yiran Qiu; Bandar Almutairy; Wenxuan Zhang; Akimasa Seno; Chitra Thakur; Fei Chen
Journal:  Antioxidants (Basel)       Date:  2021-12-29

Review 5.  Role of Nrf2 in Pancreatic Cancer.

Authors:  Marta Cykowiak; Violetta Krajka-Kuźniak
Journal:  Antioxidants (Basel)       Date:  2021-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.